MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2018 International Congress

October 5-9, 2018. Hong Kong. Abstracts are presented on the 6th, 7th, and 8th.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z
  • Nanoscale imaging reveals disorganization of the brain extracellular space in Lewy body-injected mice

    F. Soria, N. Danne, C. Paviolo, E. Doudnikoff, B. Dehay, L. Groc, L. Cognet, E. Bezard (Bordeaux, France)

  • Natural history of RBD in Parkinson´s disease and response to dopaminergic and non-dopaminergic antiparkinsonian treatment

    M. Ruiz-Lopez, V. Bruno, ME. Freitas, R. Rajalingam, A. Chang, S. Fox, A. Lang (Toronto, ON, Canada)

  • Natural occurring antibodies reduce aggregation of α-synuclein

    A. Braczynski, E. Agerschou, Y. Kronimus, W. Hoyer, R. Dodel, B. Falkenburger, J. Schulz, J. Bach (Aachen, Germany)

  • Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD

    M. Matarazzo, P. Martínez Martín, J.C. Martínez-Ávila, A. Gómez de-la-Cámara, L. Giancardo, T. Arroyo Gallego, P. Montero Escribano, V. Puertas-Martín, I. Obeso, I. Butterworth, C.S. Mendoza, M.J. Catalán, J.A. Molina-Arjona, F. Bermejo-Pareja, J.C. Martínez-Castrillo, L. López-Manzanares, A. Alonso-Canovas, J. Herreros-Rodríguez, M. Gray, Á. Sánchez-Ferro (Vancouver, BC, Canada)

  • Network analysis of symptoms in a Parkinson patient using experience sampling data: An n=1 study

    A. Mulders, R. Velden, M. Drukker, M. Kuijf, A. Leentjens (Maastricht, Netherlands)

  • Neurocognitive outcomes of STN-DBS in patients with Parkinson’s disease: A 10-year review of local experiences in Hong Kong

    V. Tang, X.L. Zhu, D. Chan, C. Lau, A. Chan, V. Mok, J. Yeung, W.S. Poon (Hong Kong)

  • Neurofilament light protein: An emerging clinical and translational biofluid biomarker for Huntington’s disease

    L. Byrne, F. Rodrigues, E. Johnson, S. Gregory, R. Soylu Kucharz, M. Björkqvist, A. Heslegrave, K. Blennow, A. Durr, B. Leavitt, R. Roos, S. Tabrizi, H. Zetterberg, D. Langbehn, R. Scahill, E. Wild (London, United Kingdom)

  • Neurohormetic properties of mild physical stress against Parkinson’s disease phenotype

    S. Kumari K.N (Zunheboto, India)

  • Neuroinflammation Predicts Dompaminergic Deficit in Early Parkinson Disease: DAT SPECT Imaging Study

    F. Rahmani, M. Rahmani (Tehran, Islamic Republic of Iran)

  • Neurologic Wilson’s Disease: Case Series on a Diagnostic and Therapeutic Emergency

    R. Porlas, L. De Castillo, C. Dioquino (Manila, Philippines)

  • Neurological improvement with WTX101 treatment in a Phase 2, multi-center, open label study in Wilson Disease

    D. Bega, J. Bronstein, D. Nicholl, F. Askari, A. Ala, P. Ferenci, C. Bjartmar, KH. Weiss, M. Schilsky, A. Czlonkowska (Chicago, IL, USA)

  • Neuromelanin Imaging and Midbrain Volumetry in Progressive Supranuclear Palsy and Parkinson’s Disease

    D. Taniguchi, T. Hatano, K. Kamagata, A. Okuzumi, M. Hori, S. Aoki, N. Hattori (Tokyo, Japan)

  • Neuromelanin sensitive MRI of substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease

    L. Jin, J. Wang, Y. Li, Z. Huang, F. Ye (Shanghai, China)

  • Neuromelanin-MRI in REM sleep behaviour disorder predicts dopaminergic dysfunction and clinical risk of Parkinson’s disease

    T. Barber, L. Griffanti, K. Bradley, D. McGowan, M. Crabbe, C. Lo, C. Mackay, J. Klein, M. Hu (Oxford, United Kingdom)

  • Neuromodulation by rTMS in Parkinsons Disease: A fMRI Study

    P. Bhat, V. Goyal, S. Kumaran, C. Goyal, A. Srivastava, M. Behari, S. Dwivedi (New Delhi, India)

  • Neuromodulatory propensity of Ginko biloba to offset rotenone induced behaviour and biochemical alteration

    K. Rode, D. Khatri, M. Panchawadkar, P. Rane (Pune, India)

  • Neuromodulatory properties of flavonoids from Persea americana Peel: Role in CNS redox homeostasis and neurobehavioral markers

    S. Grace SR, PR, J. Chauhan, G. Chandran (Mys, India)

  • Neuromodulatory role of subthalamic nucleus deep brain stimulation in Parkinson’s disease patients

    S. Szlufik, A. Przybyszewski, K. Duszynska-Was, I. Laskowska-Levy, J. Dutkiewicz, A. Drzewinska, P. Habela, T. Mandat, D. Koziorowski (Warsaw, Poland)

  • Neuronal correlates of oculomotor alterations in Huntington’s disease. A 18-FDG PET study

    J. Perez, S. Martinez Horta, F. Sampedro, J. Pagonabarraga, A. Horta, D. Lopez Mora, A. Lozano, V. Camacho, B. Gomez-Anson, J. Kulisevsky (Barcelona, Spain)

  • Neuronal KIF5b deletion induces striatum-dependent locomotor impairments and defects in membrane presentation of dopamine D2 receptors

    T. Falzone, L. Cromberg, M. Alloatti, I. Fernandez Bessone, T. Saez (Buenos Aires, Argentina)

  • Neuronal responses of pallidal and cerebellar receiving thalamic nuclei to neck exertion in cervical dystonia patients

    U. Semenova, R. Medvednik, A. Sedov (Moscow, Russian Federation)

  • Neuropathological correlates of psychiatric disorders in PD

    J. Hinkle, N. Fischer, K. Perepezko, C. Bakker, M. Broen, A. Butala, T. Dawson, A. Leentjens, Z. Mari, C. Marvel, K. Mills, E. Moukheiber, A. Pantelyat, O. Pletniková, L. Rosenthal, M. Shepard, J. Troncoso, J. Wang, G. Pontone (Baltimore, MD, USA)

  • Neuropathology of a South Korean with Perry syndrome with DCTN1 T78C mutation

    S. Kim, E. Chung, J. Baik (Busan, Republic of Korea)

  • Neuropathology of dopa-responsive dystonia due to Tyrosine hydroxylase deficiency

    S. Schreglmann, Z. Jaunmuktane, H. Jung, C. Strand, J. Holton, K. Bhatia (London, United Kingdom)

  • Neurophysiological correlates of bradykinesia in Parkinson’s disease

    M. Bologna, A. Guerra, G. Paparella, L. Giordo, D. Alunni Fegatelli, AR. Vestri, J. Rothwell, A. Berardelli (Rome, Italy)

  • Neuroprotection effects of probiotics strains on a chronic MPTP-induced mouse model of Parkinson’s disease

    Y. Qian, X. Yang, S. Xu, Q. Xiao (Shanghai, China)

  • Neuroprotective effect of exogenous melatonin on apoptosis of neuroadernergic neurons in a rat model of Parkinson’s disease

    F. Yadolahi, M. Mehrpour (Tehran, Islamic Republic of Iran)

  • Neuroprotective Effects of A Combination of Curcumin and Mucuna Prurience in Rotenone Induced Mice Model of Parkinson’s Disease

    M. Panchwadkar, P. Rane, D. Khatri, V. Undale (Pune, India)

  • Neuroprotective effects of coffee ingredients against rotenone-induced neurodegeneration in parkinsonian model

    I. Miyazaki, N. Isooka, R. Kikuoka, K. Wada, Y. Kitamura, M. Asanuma (Okayama, Japan)

  • Neuroprotective potential of curcumin in combination with piperine against 6-hydroxy dopamine induced motor deficit and neurochemical alterations in rats

    S. Singh (Moga, India)

  • Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease

    P. Kashyap, S. Gupta (Bihar, India)

  • Neuroprotective role of Tinospora cordifolia in MPTP induced Parkinsonian mouse model

    S. Singh, H. Birla, S. Rai, W. Zahra, S. Singh (Varanasi, India)

  • Neuropsychiatric and prognostic differences between functional and primary dystonia subtypes in a US specialized dystonia clinic: a case control study

    C. Stephen, D. Perez, N. Sharma (Boston, MA, USA)

  • Neuropsychiatric disorders in observed patients with Parkinson’s disease

    S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

  • Neuropsychological and clinical assessment for the differential diagnosis of patients with PDD vs. DLB

    E. Fiorenzato, L. Weis, V. Camparini, F. Pistonesi, R. Schifano, E. Gasparoli, A. Antonini, R. Biundo (Venice, Italy)

  • Neuropsychological Assessment of Cognitive Dysfunction in Parkinson’s Disease: A Comparison of Four Screening Instruments

    S. Schnitzler, L. Flitsch, S. Kaesberg, J. Kessler, E. Kalbe, M. Barbe (Cologne, Germany)

  • Neuropsychological characteristics of children with tremor

    S. O'Shea, W. Garcia, E. Louis, R. Alcalay, V. Rauh (New York, NY, USA)

  • Neuropsychological Evaluation of a Vietnamese-speaking Man with Parkinson’s Disease and Consideration for Deep Brain Stimulation Surgery: A Case Report

    B. Tran, K. Lawler (Philadelphia, PA, USA)

  • Neurorestorative effects of glycine transporter 1-inhibitor and D-Serine in a mouse model of nigrostriatal dopaminergic degeneration

    V. Francardo, Y. Schmitz, D. Sulzer, M.A. Cenci (Lund, Sweden)

  • Neurostructural alterations associated with Rapid Eye Movement Sleep Behavior Disorder in Parkinson’s disease

    C. Beal, V. Planche, C. Chassain, A. Marques, J.M. Bonny, B. Pereira, N. Vitello, M.L. Fantini, F. Durif (Clermont-Ferrand, France)

  • Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and Parkinson’s Disease: Preliminary report

    B. Lisewska, P. Lisewski, P. Szarwas, N. Piekuś-Słomka, D. Rość (Bydgoszcz, Poland)

  • New approach to assess changes in brain activation during real walking using EEG

    I. Maidan, S. Shustak, T. Shiner, N. Giladi, J. Hausdorff, A. Mirelman (Tel Aviv, Israel)

  • New evidence for thalamic dysfunction in Parkinsonian rats

    L. Grandi, G. Di Giovanni, E. Fedele, G. Orban, A. Salvadè, W. Song, A. Stefani, A. Kaelin-Lang, S. Galati (Taverne, Switzerland)

  • New Nomenclature Of Genetic Myoclonus Syndromes

    S. Veen, R. Zutt, C. Klein, C. Marras, S. Berkovic, J. Caviness, H. Shibasaki, T. De Koning, M. Tijssen (Groningen, Netherlands)

  • Nigral stimulation for the treatment of refractory gait disturbances in Parkinson’s disease

    M. Carmona-Abellán, D. Moreno, M. Alegre, J. Guridi, R. Luquin (Pamplona, Spain)

  • Nilotinib for treating MSA: A preclinical proof of concept study

    P. Guerin, M. Lopez-Cuina, E. Bezard, W. Meissner, P-O. (Bordeaux, France)

  • NMSQ Application: A New Way to Access Non-Motor Symptoms in Patients with Parkinson’s Disease

    P. Lolekha, K. Kulkantrakorn (Pathumthani, Thailand)

  • No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors

    F. Hopfner, S. Müller, D. Steppat, J. Miller, N. Schmidt, K.P. Wandinger, F. Leypoldt, D. Berg, A. Franke, W. Lieb, L. Tittmann, M. Balzer-Geldsetzer, S. Baudrexel, R. Dodel, R. Hilker-Roggendorf, E. Kalbe, J. Kassubek, T. Klockgether, I. Liepelt-Scarfone, B. Mollenhauer, P. Neuser, K. Reetz, O. Riedel, C. Schulte, J. Schulz, A. Spottke, A. Storch, C. Trenkwalder, G. Deuschl, G. Kuhlenbäumer (Kiel, Germany)

  • No deleterious effect of unilateral Gamma Knife thalamotomy on gait and posture in patients with essential tremor

    T. Witjas, E. Boutin, A. Eusebio, R. Carron, J. Régis, JP. Azulay, M. Vaugoyeau (Marseille, France)

  • No differences in the total burden of non-motor symptoms between Parkinson’s disease and non-degenerative parkinsonism

    E. Jaakkola, J. Joutsa, E. Mäkinen, T. Noponen, M. Pitkonen, R. Levo, T. Mertsalmi, F. Scheperjans, V. Kaasinen (Turku, Finland)

  • No MPTP-induced behavioral deficits or Striatal field potential alterations in crossbreds of MPTP-susceptible and MPTP-resistant mice strains

    P. Alladi, D. Vidyadhara, S. Arun, B. Kutty (Bengaluru, India)

  • Non motor symptoms in parkinsonism: A cross sectional study

    V. Kataria, V. Goyal (New Delhi, India)

  • Non-invasive, automated corneal nerve quantification reveals neurodegeneration in Parkinson’s disease: A potential novel imaging biomarker

    S. Lim, M. Ferdousi, A. Kalteniece, C. Kobylecki, R. Malik, M. Silverdale (Salford, United Kingdom)

  • Non-motor outcomes of subthalamic DBS in PD depend on the location of volume of activated tissue

    JN. Petry-Schmelzer, H. Dafsari, M. Krause, T. Dembek, A. Keyoumars, A. Rizos, M. Silverdale, J. Evans, M. Barbe, G. Fink, P. Martinez-Martin, V. Visser-Vandewalle, A. Antonini, L. Timmermann, K. Ray-Chaudhuri (Cologne, Germany)

  • Non-Motor Symptom In Young Onset Parkinson Disease as a Cause of Pharmacoresistence In Epilepsy

    M. Awadh (Birmingham, United Kingdom)

  • Non-motor symptoms and alteration of brain networks in patients with blepharospasm and hemifacial spasm

    YJ. Guo, CM. Chen, MH. Chang (Taichung, Taiwan)

  • Non-motor symptoms in Parkinson’s Disease: Frequency, types and correlated factors compared to a group of healthy controls. Results from the COPPADIS Study Cohort

    L. Planellas, M. Martí, P. Santacruz, A. Cámara, S. Jesus Maestre, F. Carrillo García, P. Mir, M. Aguilar, P. Pastor, J. García Caldentey, E. Estelrich Peyret, N. Caballol Pons, I. Legarda, B. Vives Pastor, J. Hernández Vara, G. Martí Andrés, I. Cabo, L. López Manzanares, M. Gallego-de-la-Sacristana, P. Martínez Martín, D. Santos García, G. COPPADIS STUDY (Barcelona, Spain)

  • Non-motor symptoms in patients from the Catalonian Multiple System Atrophy Registry (CMSAR)

    D.M. Giraldo, A. Pérez Soriano, J. Rios Guillermo, E. Muñoz, Y. Compta, J. Pagonabarraga, F. Valldeoriola, J. Hernández-Vara, S. Jauma Classen, V. Puente, C. Pont, N. Caballol, E. Tolosa, A. Bayes, J. Campdelacreu, O. Fabregues, A. Avila, M. Calopa, C. Gaig, N. Fabregat, P. Pastor, M. Aguilar, M. Pujol, L. Planellas, A. Camara, M.J. Marti (Barcelona, Spain)

  • Non-motor symptoms in patients with idiopathic and converted REM Sleep Behavior Disorder

    P. Chan, W. Mao, XN. Liu, SQ. Zhan, H. Zhang, Y. Li (Beijing, China)

  • Non-motor symptoms in Spinocerebellar ataxia, multiple system atrophy and Idiopathic late-onset cerebellar ataxia

    YM. Park, MJ. Kim, SB. Koh (Seoul, Republic of Korea)

  • Non-motor symptoms of Parkinson’s disease: Evaluation of urinary disorders

    K. Karbozova. (Bishkek, Kyrgyzstan)

  • Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease

    P. Prange, T. Danaila, C. Laurencin, C. Caire, E. Metereau, H. Merle, E. Broussolle, D. Maucort-Boulch, S. Thobois (Bron, France)

  • Not just runners: Adult onset lower limb dystonia

    B. Karp, D. Ehrlich, K. Alter (Bethesda, MD, USA)

  • Novel biomarkers of autonomic regulation and sleep in Parkinson’s Disease derived from Network Physiology

    O. Vaou, P. Ivanof, A. DePold-Hohler, F. Lombardi, R. Endalatpour, A. Quaicoe (Boston, MA, USA)

  • Novel CACNA1A gene mutation in a Taiwan family with episodic ataxia type 2

    KF. Chen, CH. Tsai, DC. Wu (Taichung, Taiwan)

  • Novel COMT inhibitor opicapone shows sustained inhibition and improved L-DOPA availability in monkeys

    T. Kitajima, M. Bonifácio, P. Moser, P. Soares-da-Silva, M. Tanaka (Osaka, Japan)

  • Novel GBA risk factor gene mutation p.W378R in a kindred with Gaucher’s disease and Parkinson’s disease

    M. Lubomski, M. Hayes, M. Kennerson, M. Ellis, S. Chu, J. Blackie, J. O’Sullivan, G. Nicholson (Sydney, Australia)

  • Novel mechanistic involved in targeting Parkinsons Disease by Indolocarbazole derivatives as inhibitors against Cyclin Dependent kinases using molecular modelling and simulation approaches

    S. Iqbal (Chennai, India)

  • Novel missense variants in KMT2B in segmental dystonia

    J. Ma, X.H. Wan (Beijing, China)

  • Novel population-specific mutationsin PINK1 and Parkin genes from India

    A. Kishore, M. Sturm, A. Asok, C. Schulte, D. KP, S. Krishnan, O. Riess, M. Sharma (Trivandrum, India)

  • Nucleotide repeats as genetic risk factors in a Swedish Parkinson’s disease cohort

    J. Laffita Mesa, L. Brodin, P. Svenningsson (Stockholm, Sweden)

  • Nurr1 gene: A new research target for Parkinson’s disease

    W. Le (Dalian, China)

  • Nursing diagnoses, outcomes and ICNP® interventions related to urinary dysfunction in Parkinson’s disease

    M. Tosin, B. Oliveira (Santos-SP, Brazil)

Jump to:  View All • a b c d e f g h i j k l m [n] o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley